Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis

Petra Baji (), Márta Péntek, Sándor Szántó, Pál Géher, László Gulácsi, Orsolya Balogh and Valentin Brodszky
Additional contact information
Petra Baji: Corvinus University of Budapest
Márta Péntek: Corvinus University of Budapest
Sándor Szántó: University of Debrecen Medical and Health Sciences Center
Pál Géher: Budai Irgalmasrendi Hospital
László Gulácsi: Corvinus University of Budapest
Orsolya Balogh: Corvinus University of Budapest

The European Journal of Health Economics, 2014, vol. 15, issue 1, No 6, 45-52

Abstract: Abstract Objectives To compare the efficacy and safety of infliximab-biosimilar with other biological drugs for the treatment of active ankylosing spondylitis (AS). Methods Systematic literature review for randomized controlled trials (RCTs) with adalimumab, etanercept, golimumab, infliximab and infliximab-biosimilar in AS was performed and indirect meta-analysis (Bayesian mixed treatment comparison) was carried out. The proportion of patients reaching 20 % improvement by the assessment of Spondyloarthritis International Society response criteria (ASAS20) at weeks 12 and 24 was used as efficacy endpoints, and the occurrence of serious adverse events at week 24 was applied to compare the safety of the biologicals. Results Altogether, 13 RCTs, identified by the systematic literature search, were included in the analysis. Results on the ASAS20 efficacy endpoint were reported for week 12 in 12 RCTs involving 2,395 patients, and for week 24 in 5 RCTs comprising 1,337 patients. All the five biological agents proved to be significantly superior to placebo. Infliximab showed the highest odds ratio (OR) of 7.2 (95 % CI 3.68–13.19) compared to placebo, followed by infliximab-biosimilar with OR 6.25 (95 % CI 2.55–13.14), both assessed at week 24. No significant difference was found between infliximab-biosimilar and other biological treatments regarding their efficacy and safety. Conclusions This is the first study which includes a biosimilar drug in the meta-analysis of biological treatments in AS. The results have proven the similar efficacy and safety profile of infliximab-biosimilar treatment compared to other biologicals.

Keywords: Ankylosing spondylitis; Biological drug; Biosimilar pharmaceuticals; Meta-analysis; Efficacy; Safety (search for similar items in EconPapers)
JEL-codes: I10 I19 (search for similar items in EconPapers)
Date: 2014
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s10198-014-0593-5 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
Journal Article: Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis (2014)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:15:y:2014:i:1:d:10.1007_s10198-014-0593-5

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-014-0593-5

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().